Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
https://european-biotechnology.com/wp-content/uploads/2024/04/Versantis.jpg10822048Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-19 08:16:112019-09-19 08:16:11Versantis raises CHF16m in Series B financing
https://european-biotechnology.com/wp-content/uploads/2024/04/ICU-banner-666x300.jpg300666Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-13 07:47:382019-09-13 07:47:38Inotrem SA raises €39m to provide POC for nangibotide
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-09-12_um_07.02.33.png663990Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-12 06:22:182019-09-12 06:22:18Ermium Therapeutics bags €6.3m in Series A round
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2019-09-11_um_08.31.36.png519881Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-09-11 07:44:522019-09-11 07:44:52Pharvaris BV raises $66m to advance oral HAE drug
London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
New malaria lead kills 99.9% of pathogens
Latest NewsDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Versantis raises CHF16m in Series B financing
Latest NewsSwiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Lundback swallows migraine drug maker Alder
Latest NewsDanish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc.
PFF Group NV acquires stake in Autolus Therapeutics
Latest NewsPrague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
Elcin Barker Ergun becomes Menarini CEO
AppointmentsThe Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.
Researchers identify CTLA-4 response marker
Latest NewsGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises €39m to provide POC for nangibotide
Latest NewsFrench biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags €6.3m in Series A round
Latest NewsParis-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
Latest NewsLeiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
4BIO Ventures launches US$50m fund
Latest NewsLondon and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.